Tesaglitazar: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(Undo revision 1709717 by Javaria Anwer (talk))
Tag: Undo
 
Line 28: Line 28:
'''Tesaglitazar''' is a proposed treatment for [[type 2 diabetes]].<ref name="pmid17907109">{{cite journal |author=Wilding JP, Gause-Nilsson I, Persson A |title=Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes |journal=Diab Vasc Dis Res |volume=4 |issue=3 |pages=194-203 |year=2007 |pmid=17907109 |doi=10.3132/dvdr.2007.040 |url=http://dx.doi.org/10.3132/dvdr.2007.040}}</ref>   
'''Tesaglitazar''' is a proposed treatment for [[type 2 diabetes]].<ref name="pmid17907109">{{cite journal |author=Wilding JP, Gause-Nilsson I, Persson A |title=Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes |journal=Diab Vasc Dis Res |volume=4 |issue=3 |pages=194-203 |year=2007 |pmid=17907109 |doi=10.3132/dvdr.2007.040 |url=http://dx.doi.org/10.3132/dvdr.2007.040}}</ref>   


*[[SGLT2]] inhibitors have been reported to lower all-cause [[mortality]], reduced hospitalisation for [[heart failure]], lowering [[weight]].<ref name="PalmerTendal2021">{{cite journal|last1=Palmer|first1=Suetonia C|last2=Tendal|first2=Britta|last3=Mustafa|first3=Reem A|last4=Vandvik|first4=Per Olav|last5=Li|first5=Sheyu|last6=Hao|first6=Qiukui|last7=Tunnicliffe|first7=David|last8=Ruospo|first8=Marinella|last9=Natale|first9=Patrizia|last10=Saglimbene|first10=Valeria|last11=Nicolucci|first11=Antonio|last12=Johnson|first12=David W|last13=Tonelli|first13=Marcello|last14=Rossi|first14=Maria Chiara|last15=Badve|first15=Sunil V|last16=Cho|first16=Yeoungjee|last17=Nadeau-Fredette|first17=Annie-Claire|last18=Burke|first18=Michael|last19=Faruque|first19=Labib I|last20=Lloyd|first20=Anita|last21=Ahmad|first21=Nasreen|last22=Liu|first22=Yuanchen|last23=Tiv|first23=Sophanny|last24=Millard|first24=Tanya|last25=Gagliardi|first25=Lucia|last26=Kolanu|first26=Nithin|last27=Barmanray|first27=Rahul D|last28=McMorrow|first28=Rita|last29=Raygoza Cortez|first29=Ana Karina|last30=White|first30=Heath|last31=Chen|first31=Xiangyang|last32=Zhou|first32=Xu|last33=Liu|first33=Jiali|last34=Rodríguez|first34=Andrea Flores|last35=González-Colmenero|first35=Alejandro Díaz|last36=Wang|first36=Yang|last37=Li|first37=Ling|last38=Sutanto|first38=Surya|last39=Solis|first39=Ricardo Cesar|last40=Díaz González-Colmenero|first40=Fernando|last41=Rodriguez-Gutierrez|first41=René|last42=Walsh|first42=Michael|last43=Guyatt|first43=Gordon|last44=Strippoli|first44=Giovanni F M|title=Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials|journal=BMJ|year=2021|pages=m4573|issn=1756-1833|doi=10.1136/bmj.m4573}}</ref>
The drug had completed several [[clinical_trial#Phase_III|phase III clinical trial]]s,<ref name="title">{{cite web | url = http://www.astrazenecaclinicaltrials.com/ncmprintchapter.aspx?type=article&param=520974 | title = GALIDA™ (tesaglitazar) Clinical Trial Report Summaries | accessdate = 2008-03-17 | author = | authorlink = | coauthors = | date = | format = | work = | publisher = AstraZeneca | pages = | language = | archiveurl = | archivedate = | quote = }}</ref> however in May, 2006  [[AstraZeneca]] announced that it had discontinued  further development.<ref name="AstraZeneca_tesaglitazar_press_release)">{{cite web | url = http://www.astrazeneca.com/pressrelease/5240.aspx | title = AstraZeneca Discontinues Development of GALIDA (tesaglitazar) | accessdate = 2008-03-17 | author = | authorlink = | coauthors = | date = 2006-05-04 | format = | work = | publisher = AstraZeneca  | pages = | language = | archiveurl = | archivedate = | quote = }}</ref>
The drug had completed several [[clinical_trial#Phase_III|phase III clinical trial]]s,<ref name="title">{{cite web | url = http://www.astrazenecaclinicaltrials.com/ncmprintchapter.aspx?type=article&param=520974 | title = GALIDA™ (tesaglitazar) Clinical Trial Report Summaries | accessdate = 2008-03-17 | author = | authorlink = | coauthors = | date = | format = | work = | publisher = AstraZeneca | pages = | language = | archiveurl = | archivedate = | quote = }}</ref> however in May, 2006  [[AstraZeneca]] announced that it had discontinued  further development.<ref name="AstraZeneca_tesaglitazar_press_release)">{{cite web | url = http://www.astrazeneca.com/pressrelease/5240.aspx | title = AstraZeneca Discontinues Development of GALIDA (tesaglitazar) | accessdate = 2008-03-17 | author = | authorlink = | coauthors = | date = 2006-05-04 | format = | work = | publisher = AstraZeneca  | pages = | language = | archiveurl = | archivedate = | quote = }}</ref>


Latest revision as of 15:04, 2 August 2021

Tesaglitazar
File:Tesaglitazar.png
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H24O7S
Molar mass408.46
3D model (JSmol)

Tesaglitazar is a proposed treatment for type 2 diabetes.[1]

The drug had completed several phase III clinical trials,[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.[3]

References

  1. ↑ Wilding JP, Gause-Nilsson I, Persson A (2007). "Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes". Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
  2. ↑ "GALIDA™ (tesaglitazar) Clinical Trial Report Summaries". AstraZeneca. Retrieved 2008-03-17.
  3. ↑ "AstraZeneca Discontinues Development of GALIDA (tesaglitazar)". AstraZeneca. 2006-05-04. Retrieved 2008-03-17.

Template:Pharma-stub Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Tesaglitazar&oldid=1709788"